"Ocrelizumab is a humanized anti-CD20 monoclonal antibody, hence a CD20 antagonist. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It is under development for multiple sclerosis by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec."
In October 2010, Roche announced 24-week results from the PhII study in relapsing-remitting MS. The drug demonstrated a statistically significant reduction in disease activity as measured by brain lesions (measured by MRI scans) and relapse rate compared to placebo. Both doses (200 mg and 600 mg) were well tolerated.
On October 8th, 2015, Genentech announced the results of threePhase III clinical trials that look promising.
Vitamin D3 Discount - iHerb!
Healthy Origins 5,000iu 360 Vitamin D3 softgels
Coconut Oil Discount - iHerb!
Powered Kale Discount - iHerb!